Paper Search Console

Home Search Page About Contact

Journal Title

Title of Journal: J Thromb Thrombolysis

Search In Journal Title:

Abbravation: Journal of Thrombosis and Thrombolysis

Search In Journal Abbravation:

Publisher

Springer US

Search In Publisher:

DOI

10.1016/0375-9474(83)90350-0

Search In DOI:

ISSN

1573-742X

Search In ISSN:
Search In Title Of Papers:

Cardiovascular risk factors and outcome in patient

Authors: Mirko Di Capua Antonio Coppola Rosina Albisinni Antonella Tufano Anna Guida Matteo Nicola Dario Di Minno Ferdinando Cirillo Marcello Loffredo Anna Maria Cerbone
Publish Date: 2009/08/25
Volume: 30, Issue: 1, Pages: 16-22
PDF Link

Abstract

The pathogenesis and treatment of retinal vein occlusions RVO are largely unclear Prevalence of cardiovascular risk factors and of thrombophilic abnormalities was evaluated in 117 patients 61 M 56 F mean age 51 ± 13 years with a history of RVO 62 central CRVO 48 branch BRVO 7 both and in 202 age and sexmatched control subjects Cardiovascular outcome after a mean 82 year followup was recorded for 90 patients Arterial hypertension was significantly more frequent in patients than in controls 649 vs 282 adjusted OR 45 95 CI 24–79 P  00001 as well diabetes mellitus 179 vs 79 P  005 Antithrombin Protein C Protein S and homocysteine levels lupus anticoagulant anticardiolipin antibodies FV G1691A and prothrombin G20210A polymorphisms were comparable in the two groups nor were different according to RVO localization or to the age at event BRVO patients were significantly older 55 ± 9 vs 47 ± 15 years P = 0002 and had higher prevalence of diabetes overweight and hypertension 292 vs 81 833 vs 581 792 vs 565 P always 005 In 58/90 64 patients for whom clinical followup was available new vascular events were recorded coronary/cerebral n = 38 only 22 patients 24 received longterm antiplatelet agents mostly aspirin 100 mg/d with lower but not statistically significant prevalence of overall vascular recurrence 454 vs 706 P = 006 High rate of vascular recurrence is shown in patients with previous RVO in which conventional cardiovascular risk factors play a major role especially in BRVO and in older patients


Keywords:

References


.
Search In Abstract Of Papers:
Other Papers In This Journal:

  1. The inhibition in tumor necrosis factor-α-induced attenuation in endothelial thrombomodulin expression by carvedilol is mediated by nuclear factor-κB and reactive oxygen species
  2. Comparison of platelet inhibition by prasugrel versus ticagrelor over time in patients with acute myocardial infarction
  3. Does supervised exercise after deep venous thrombosis improve recanalization of occluded vein segments? A randomized study
  4. Anticoagulation in the management of venous thromboembolism in the cancer patient
  5. Association between sleep condition and arterial stiffness in Chinese adult with nonalcoholic fatty liver disease
  6. In vitro shear stress modulates antithrombogenic potentials of human endothelial progenitor cells
  7. Polymorphism in the methylenetetrahydrofolate reductase (C677T) gene and homocysteine levels: a comparison in Brazilian patients with coronary arterial disease, ischemic stroke and peripheral arterial obstructive disease
  8. Role of thrombophilia testing: con
  9. Venous thromboembolism and cancer: a systematic review
  10. Dabigatran-associated subdural hemorrhage: using thromboelastography (TEG ® ) to guide decision-making
  11. Proceedings of the 10th National Conference on Anticoagulant Therapy
  12. Comparative efficacy of in vitro and in vivo metabolized aspirin in the DeBakey ventricular assist device
  13. The relationship between gender and age with monocyte tissue factor expression
  14. Determination of rivaroxaban by different factor Xa specific chromogenic substrate assays: reduction of interassay variability
  15. A comparison of direct thrombin inhibitors in the treatment of heparin-induced thrombocytopenia: a single institution experience
  16. US Food and Drug Administration approval of generic versions of complex biologics: implications for the practicing physician using low molecular weight heparins
  17. Measurement of dabigatran and rivaroxaban in primary prevention of venous thromboembolism in 106 patients, who have undergone major orthopedic surgery: an observational study
  18. Abnormal asymmetric dimethylarginine/nitric oxide balance in patients with documented coronary artery disease: relation to renal function and homocysteine
  19. Tailoring clopidogrel dose according to multiple electrode aggregometry decreases the rate of ischemic complications after percutaneous coronary intervention
  20. Impact of type of thrombolytic agent on in-hospital outcomes in ST-segment elevation myocardial infarction patients in the Middle East
  21. Prognostic significance of multidetector computed tomography in normotensive patients with pulmonary embolism: rationale, methodology and reproducibility for the PROTECT study
  22. Increased platelet activation in patients with slow coronary flow
  23. Biomarkers of deep venous thrombosis
  24. Thromboembolic complications following a first isolated episode of superficial vein thrombosis: a cross-sectional retrospective study
  25. The impact of factor Xa inhibition on axial dependent arterial thrombus formation triggered by a tissue factor rich surface
  26. New oral Xa and IIa inhibitors: updates on clinical trial results
  27. Spontaneous coronary thrombosis following thrombolytic therapy for acute cardiovascular accident and stroke: a case study
  28. Anti-coagulant activity of a metalloprotease: further characterization from the Indian cobra ( Naja naja ) venom
  29. Evaluation of the Alere D-dimer test for point of care testing
  30. Strategies and outcomes of periprocedural bridging therapy with low-molecular-weight heparin in patients with mechanical heart valves
  31. Elevated concentration of placental growth factor (PlGF) and long term risk in patients with acute coronary syndrome in the PROVE IT-TIMI 22 trial
  32. Association between micro particle-tissue factor activity, factor VIII activity and recurrent VTE in patients with acute pulmonary embolism
  33. Methylenetetrahydrofolate reductase (MTHFR) C677T genetic polymorphism and late infarct-related coronary artery patency after thrombolysis
  34. Are surgical patients at risk of venous thromboembolism currently meeting the Surgical Care Improvement Project performance measure for appropriate and timely prophylaxis?
  35. Evaluation of von Willebrand factor and ADAMTS-13 antigen and activity levels in sickle cell disease patients in Kuwait

Search Result: